Φορτώνει......
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + ME...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Discov |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007378/ https://ncbi.nlm.nih.gov/pubmed/31796433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0672 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|